Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomes

HUEY-LING CHENCHIEN-NAN LEEChang, Chin-HaoChin-HaoChangLai, Ming-WeiMing-WeiLaiTsai, Ming-ChiehMing-ChiehTsaiMu, Shu-ChiShu-ChiMuCHUN-JEN LIUWen, Wan-HsinWan-HsinWenHu, Rui-TingRui-TingHuHuang, Chun-PinChun-PinHuangJIN-CHUNG SHIHHu, Kuang-ChunKuang-ChunHuChen, Chie-PeinChie-PeinChenLee, Chyi-LongChyi-LongLeeChien, Rong-NanRong-NanChienKAI-CHI CHANGHONG-YUAN HSUCHIEN-CHANG LEEYEN-HSUAN NIMEI-HWEI CHANG2024-03-292024-03-292024-03-0814783223https://scholars.lib.ntu.edu.tw/handle/123456789/641599The use of antiviral agents, specifically tenofovir disoproxil fumarate (TDF), in pregnant women to prevent mother-to-child HBV transmission is a key step towards hepatitis elimination. However, data on using tenofovir alafenamide (TAF) is insufficient. The frequent occurrence of postpartum ALT flares may impact the clinical implementation.enHBV immunization; HBeAg; antiviral therapy; children; hepatitis B virus; mother-to-infant transmission; nucleoside analogue; pregnancy; pregnant women[SDGs]SDG3Tenofovir alafenamide or tenofovir disoproxil fumarate in pregnancy to prevent HBV transmission: Maternal ALT trajectory and infant outcomesjournal article10.1111/liv.15873384566202-s2.0-85187161655https://api.elsevier.com/content/abstract/scopus_id/85187161655